These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 8324866)
1. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Wientjes MG; Badalament RA; Au JL Cancer Chemother Pharmacol; 1993; 32(4):255-62. PubMed ID: 8324866 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640 [TBL] [Abstract][Full Text] [Related]
3. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. Erdogar N; İskit AB; Eroglu H; Sargon MF; Mungan NA; Bilensoy E Int J Pharm; 2014 Aug; 471(1-2):1-9. PubMed ID: 24836669 [TBL] [Abstract][Full Text] [Related]
4. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559 [TBL] [Abstract][Full Text] [Related]
5. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. Au JL; Badalament RA; Wientjes MG; Young DC; Warner JA; Venema PL; Pollifrone DL; Harbrecht JD; Chin JL; Lerner SP; Miles BJ; J Natl Cancer Inst; 2001 Apr; 93(8):597-604. PubMed ID: 11309436 [TBL] [Abstract][Full Text] [Related]
6. Penetration of mitomycin C in human bladder. Wientjes MG; Badalament RA; Wang RC; Hassan F; Au JL Cancer Res; 1993 Jul; 53(14):3314-20. PubMed ID: 8324743 [TBL] [Abstract][Full Text] [Related]
7. Penetration of intravesical doxorubicin in human bladders. Wientjes MG; Badalament RA; Au JL Cancer Chemother Pharmacol; 1996; 37(6):539-46. PubMed ID: 8612307 [TBL] [Abstract][Full Text] [Related]
8. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine. Gao X; Au JL; Badalament RA; Wientjes MG Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962 [TBL] [Abstract][Full Text] [Related]
9. The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration. Cliff AM; Heatherwick B; Scoble J; Parr NJ BJU Int; 2000 Oct; 86(6):644-7. PubMed ID: 11069370 [TBL] [Abstract][Full Text] [Related]
10. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs. Hu L; Wientjes MG; Li J; Au JL AAPS J; 2010 Dec; 12(4):586-91. PubMed ID: 20625863 [TBL] [Abstract][Full Text] [Related]
11. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Yen WC; Schmittgen T; Au JL Pharm Res; 1996 Dec; 13(12):1887-91. PubMed ID: 8987090 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. De Bruijn EA; Sleeboom HP; van Helsdingen PJ; van Oosterom AT; Tjaden UR; Maes RA Int J Cancer; 1992 May; 51(3):359-64. PubMed ID: 1592527 [TBL] [Abstract][Full Text] [Related]
13. [Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment]. Lailler G; Neuzillet Y; Rouanne M; Lebret T Prog Urol; 2016 Feb; 26(2):79-82. PubMed ID: 26653577 [TBL] [Abstract][Full Text] [Related]
14. Bladder wall penetration of intravesical mitomycin C in dogs. Wientjes MG; Dalton JT; Badalament RA; Drago JR; Au JL Cancer Res; 1991 Aug; 51(16):4347-54. PubMed ID: 1907883 [TBL] [Abstract][Full Text] [Related]
15. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Tan WP; Chang A; Brousell SC; Grimberg DC; Fantony JJ; Longo TA; Etienne W; Spasojevic I; Maccarini P; Inman BA Int J Hyperthermia; 2020; 37(1):854-860. PubMed ID: 32664768 [TBL] [Abstract][Full Text] [Related]
17. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010 [TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. Abbo AH; Jones DR; Masters AR; Stewart JC; Fourez L; Knapp DW J Vet Intern Med; 2010; 24(5):1124-30. PubMed ID: 20695986 [TBL] [Abstract][Full Text] [Related]
19. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034 [TBL] [Abstract][Full Text] [Related]
20. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]